Advertisement

Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings

  • S. Henriot
  • C. Kuhn
  • R. Kettler
  • M. Da Prada
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)

Summary

Ro 19-6327 (lazabemide, L), MDL 72974, selegiline, AGN 1135 and MDL 72145 were investigated for their MAO inhibitory effect in rat tissues in vitro. The selectivity of MAO-B inhibition of L, selegiline and MDL 72974 was also measured in vitro in human brain tissue as well as ex vivo in rat brain and liver after acute and subchronic administration. Of all compounds investigated L was the most selective for MAO-B inhibition under in vitro and ex vivo conditions. In volunteers, L completely but reversibly inhibited platelet MAO-B with a dose-dependent duration. Clinical trials with L are under way in both Alzheimer’s and Parkinson’s disease (PD).

Keywords

Human Brain Tissue Nigrostriatal Dopaminergic Neuron Subchronic Administration Neurochemical Profile Selective Monoamine Oxidase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bench CG, Prince GW, Lammertsma AA, Cremer JC, Luthra SK, Turton D, Dolan RJ, Kettler R, Dingemanse J, Da Prada M, Bizière M, McClelland GR, Jamieson VL, Wood NB, Frackowiak RSJ (1991) Measurement of human cerebral mono-amine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibidor Ro 19-6327. Eur J Clin Pharmacol 40: 169–173.PubMedCrossRefGoogle Scholar
  2. Birkmayer W, Riederer P, Youdim MBH (1982) (-)Deprenyl in the treatment of Parkinson’s disease. Clin Neuropharmacol 5: 195–230.PubMedCrossRefGoogle Scholar
  3. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monamine oxidase type A. J Pharmacol Exp Ther 248: 400–414.PubMedGoogle Scholar
  4. Dingemanse J, Kettler R, Schmitt M, Fotteler B, Da Prada M (1991) Clinical pharmacology of selective inhibitors of MAO-B and COMT. Abstract F-19-05, 10th International Symposium on Parkinson’s Disease. October 27–30, Tokyo.Google Scholar
  5. Haefely WE, Kettler R, Keller HH, Da Prada M (1990) Ro 19-6327, a reversible and highly selective monoamine oxidase B inhibitor: a novel tool to explore the MAO-B functions in humans. Adv Neurol 53: 505–512.PubMedGoogle Scholar
  6. Kettler R, Da Prada M (1989) Platelet MAO-B activity in humans and stump-tail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro 19-6327’. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 213–219.CrossRefGoogle Scholar
  7. Sunderland T, Mueller EA, Cohen RM (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 9: 432–437.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • S. Henriot
    • 1
  • C. Kuhn
    • 1
  • R. Kettler
    • 1
  • M. Da Prada
    • 1
  1. 1.Pharma Division, Preclinical ResearchF. Hoffmann La-Roche LtdBaselSwitzerland

Personalised recommendations